Track topics on Twitter Track topics that are important to you
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics. The company maintains a solid intellectual property position with its strong portfolio of potential breakthrough products now in clinical development and several pre-clinical programs. The lead products are human recombinant proteins: AEROVANT™, an IL-4 and IL-13 receptor antagonist currently in Phase 2a studies for asthma; AEROLYTIC™, a serine protease inhibitor in Phase 2a for Cystic Fibrosis; AERODERM™, an IL-4 and IL-13 receptor antagonist in Phase 2a for eczema, and PULMOLYTIC™, a serine protease inhibitor in Phase 2a for COPD.
Aerovance was spun off from Bayer Healthcare's biotechnology unit in August 2004 and has a proven executive team, experienced in the field of respiratory disease and biologics drug development. The company’s venture capital investors are Alta Partners, APAX Partners, Burrill & Company, Clarus Ventures, Lehman Brothers and NGN Capital.
2929 7th StreetSuite 130
United States of America
Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics. The company maintains a solid intellectual property position with its str...
We have published hundreds of AEROVANCE, INC news stories on BioPortfolio along with dozens of AEROVANCE, INC Clinical Trials and PubMed Articles about AEROVANCE, INC for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of AEROVANCE, INC Companies in our database. You can also find out about relevant AEROVANCE, INC Drugs and Medications on this site too.
The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...
Affecting over 8,500 people in the UK, Cystic Fibrosis (CF) is one of the UK's most common life-threatening inherited diseases. Around half of the CF population can expect to live over 38 years, although improvements in treatments mean a baby born ...